GeneproDX
PrivateLast Round
Early Funding
Feb 14, 2022
Est. Valuation
$135M
Total Funding Raised
$2.34M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
GeneproDX is a biotechnology company that develops molecular diagnostic tests, including the ThyroidPrint genomic classifier, to aid in the management of indeterminate thyroid nodules.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Usage-Based SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GeneproDX Comparables
Compare GeneproDX with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Biocartis | 80% | |
| Sonic Healthcare | 74% | |
| Veracyte | 72% | |
GeneproDX Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Feb 14, 2022 | ||||
| VC Round | Apr 17, 2018 | ||||
| VC Round | Dec 12, 2017 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors grew 153% MoM.
- Mar 2, 2026
Monthly visitors increased 34% MoM.
GeneproDX Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about GeneproDX's valuation, stock price, and market status.